Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer

被引:89
作者
Hoeller, U
Borgmann, K
Bonacker, M
Kuhlmey, A
Bajrovic, A
Jung, H
Alberti, W
Dikomey, E
机构
[1] Univ Hamburg, Hosp Eppendorf, Inst Biophys & Radiobiol, D-20246 Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Dept Radiotherapy & Radiooncol, D-20246 Hamburg, Germany
[3] Univ Hamburg, Hosp Eppendorf, Dept Diagnost & Intervent Radiol, D-20246 Hamburg, Germany
关键词
individual radiosensitivity; chromosome aberrations; predictive test; late tissue response; fibrosis;
D O I
10.1016/j.radonc.2003.10.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To analyse the relationship of individual cellular radiosensitivity and fibrosis after breast conserving therapy. A new model was used describing the percentage of patients developing fibrosis per year and per patient at risk. Patients and methods: In a retrospective study, 86 patients were included, who had undergone breast conserving surgery and irradiation of the breast with a median dose of 55 Gy (54-55 Gy) given at 2.5 Gy/fraction (n = 57) or 2 Gy/fraction (n = 29). Median age was 62 years (range 44-86) and median follow-up was 7.5 years (range 5-17). Patients were examined for fibrosis according to the LENT/SOMA score. For analysis, fibrosis was classified as grade 0 and grade 1 (G0-1) or present grade 2 and grade 3 (G2-3). The time to complete development of fibrosis was determined by analysis of yearly mammograms. Individual cellular radiosensitivity was determined by scoring lethal chromosomal aberrations in in vitro irradiated (6 Gy) lymphocytes using metaphase technique. Patients with low/intermediate cellular radiosensitivity were compared with patients with high cellular radiosensitivity using actuarial methods. Results: Ten patients developed fibrosis at 1-8 years after radiotherapy. Individual cellular radiosensitivity was described by normal distribution of lethal chromosomal aberrations, the average was 5.47 lethal aberrations per cell (standard deviation (SD) 0.71). Cellular radiosensitivity was defined as low/intermediate (less than or equal to6.18 lethal aberrations) in 73 patients and high (>6.18 lethal aberrations; mean + SD) in 13 patients. In both groups, the actuarial rate of fibrosis-free patients decreased exponentially with time after radiotherapy. Patients with high cellular radiosensitivity showed a 2.3-fold higher annual rate for fibrosis than patients with intermediate and low radiosensitivity (3.6 versus 1.6% per year). Conclusions: In breast cancer patients, high individual cellular radiosensitivity as determined by the number of lethal chromosome aberrations in in vitro irradiated lymphocytes might be associated with an enhanced annual rate of fibrosis. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 47 条
[1]   Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it? [J].
Andreassen, CN ;
Alsner, J ;
Overgaard, J .
RADIOTHERAPY AND ONCOLOGY, 2002, 64 (02) :131-140
[2]   Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer [J].
Barber, JBP ;
Burrill, W ;
Spreadborough, AR ;
Levine, E ;
Warren, C ;
Kiltie, AE ;
Roberts, SA ;
Scott, D .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (02) :179-186
[3]  
Bentzen, 1994, Semin Radiat Oncol, V4, P68, DOI 10.1016/S1053-4296(05)80034-7
[4]  
Bentzen S M, 1993, Recent Results Cancer Res, V130, P59
[5]   Potential clinical impact of normal-tissue intrinsic radiosensitivity testing [J].
Bentzen, SM .
RADIOTHERAPY AND ONCOLOGY, 1997, 43 (02) :121-131
[6]   LATENT-TIME ESTIMATION FOR LATE CUTANEOUS AND SUBCUTANEOUS RADIATION REACTIONS IN A SINGLE-FOLLOW-UP CLINICAL-STUDY [J].
BENTZEN, SM ;
THAMES, HD ;
OVERGAARD, M .
RADIOTHERAPY AND ONCOLOGY, 1989, 15 (03) :267-274
[7]  
Bentzen SM, 1998, RADIOTHER ONCOL, V46, P216
[8]   DOSE AND VOLUME EFFECTS ON FIBROSIS AFTER BREAST-CONSERVATION THERAPY [J].
BORGER, JH ;
KEMPERMAN, H ;
SMITT, HS ;
HART, A ;
VANDONGEN, J ;
LEBESQUE, J ;
BARTELINK, H .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (05) :1073-1081
[9]   CONSERVATIVE BREAST-CANCER-TREATMENT - ANALYSIS OF COSMETIC RESULTS AND THE ROLE OF CONCOMITANT ADJUVANT CHEMOTHERAPY [J].
BORGER, JH ;
KEIJSER, AH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (08) :1173-1177
[10]  
BORGER JH, 1994, INT J RAD BIOL PHYS, V30, P1994